Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carboplatin and Bevacizumab for Recurrent Ependymoma
NCT01295944Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Apr 2011
- Primary completion
- Sep 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in ependymoma, sponsored by National Cancer Institute. Started Apr 2011; status: completed.
02
Drugs
bevacizumab
03
Conditions
ependymoma
Beyond the preview
Go deeper on NCT01295944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01295944.